Dynamin-related protein 1 (DRP1), an 80 kDa GTPase, is involved in mitochondrial fission and anticancer drugmediated cytotoxicity, which implicate an association with disease progression of cancer. In this study we investigated the prognostic value of DRP1 in lung adenocarcinomas. Using immunohistochemistry, we measured the expression of DRP1 in 227 patients with lung adenocarcinomas. Expression of DRP1 was confirmed by immunoblotting. The correlation between DRP1 expression and clinicopathological parameters was analyzed by statistical analysis. Difference of survivals between different groups was compared by a logrank test. The results showed that DRP1 expression was detected in 202 patients with lung adenocarcinomas. Among these, nuclear DRP1 (DRP1 nuc ) was detected in 184 patients. A significant difference was found in cumulative survival between patients with high DRP1 nuc levels and those with DRP1 cyt levels (Po0.001). In vitro, hypoxia increased DRP1 nuc levels and cisplatin resistance. Antibodies specific to DRP1 co-precipitated a human homologue of yeast Rad23 protein A (hHR23A) and silencing of hHR23A decreased the nuclear DRP1 level and cisplatin resistance. In conclusion, DRP1 nuc is highly expressed in lung adenocarcinomas, and correlates with poor prognosis. Nuclear DRP1 may increase drug resistance during hypoxia, and hHR23A is essential for nuclear transportation of DRP1. Our results suggest that other than the protein level alone, intracellular distribution of the protein is critical for determining the protein function in cells.
Mitochondria are one of the major organelles responsible for intracellular regulation of programmed cell death. Interestingly, although three types of programmed cell death have been characterized and each has its own cellular features, 1, 2 dynamin-related protein 1 (DRP1) and mitochondria are involved in all three types of programmed cell death. [2] [3] [4] DRP1 is an 80 kDa GTPase belonging to the dynamin superfamily, which mediates budding and scission of a variety of vesicles and organelles inside cells. Dynamins are required for fission of peroxisomes and mitochondria, 5 in particular, the later one at mitosis. 6 It has been demonstrated that during fission DRP1 is recruited by human homologue of yeast fission protein 1 (hFis1) to a punctuate structure on mitochondrial outer membrane, thereby acting as a mechanoenzyme to mediate membrane constriction. 7, 8 A number of commonly used anticancer drugs, such as epipodophyllotoxins and cisplatin, accelerate organelle fission, and convincing evidence indicates that mitochondrial fragmentation is closely associated with cytotoxicity of these drugs. 3, 9, 10 Therefore, a better understanding of DRP1 expression and activity would be useful in improving the efficacy of these chemotherapeutic agents. In addition, these drugs might prove to be valuable probes in characterizing the fundamental function and control mechanism of DRP1 and other fusion/fission-related proteins in mitochondrial fragmentation and membrane shuttling of organelles. However, DRP1 has not been studied in non-small-cell lung cancer, in particular, the lung adenocarcinomas, of which the incidence and mortality have increased dramatically in the past two decades. Treatment failures, which are mainly caused by DNA repair-and hypoxiaassociated drug and radiation resistance, 11, 12 are major reasons for the high disease-related mortality.
In this study, we used immunohistochemistry and immunoblotting to determine DRP1 expression in lung adenocarcinomas. We also evaluated the statistical correlation between the expression of DRP1 and the clinicopathological parameters of patients with lung adenocarcinomas as well as the prognostic significance of DRP1 expression in patients with lung adenocarcinomas. This study also investigated the effect of hypoxia on DRP1 expression and drug resistance in vitro.
Materials and methods

Tissue Specimens and Lung Cancer Cell Lines
We evaluated pathology specimens from 468 patients in whom non-small-cell lung cancer had been diagnosed during the period from August 1986 to November 2003. Among these patients, lung adenocarcinomas had been diagnosed in 227 patients. Stage of the disease was classified (in patients admitted after 1999) or re-classified (in patients admitted before 1999) according to the new international staging system for lung cancer. 13 The medical ethics committee of the China Medical University Hospital approved the protocol, and written informed consent to donate biopsy specimens was obtained from each patient. All patients had undergone surgical resection and radical N2 lymph node dissection, followed with six cycles of cisplatin-based chemotherapy. After treatment, patients were routinely followed every 3-6 months in outpatient department. Immunohistochemical staining was carried out using a single-blinded procedure.
Seven lung cancer cell lines (H23, H226, H838, H1437, H2009, H2087 and A549) and one uterine cervical cancer line (HeLa) were used to evaluate DRP1 expression in vitro. Among those, H23, H838, H1437, H2009, H2087 and A549 are lung adenocarcinoma cells, and H226 is an epithelial type. The cell culture conditions used in this study have been described previously.
14 Hypoxia was induced by incubating cultured cells with 1.0% O 2 and 5% CO 2 for more than 3 h.
Reverse Transcription-Polymerase Chain Reaction and Preparation of Monoclonal Antibodies
Following total RNA extraction and first-strand cDNA synthesis, an aliquot of cDNA was subjected to 35 cycles of PCR to determine the integrity of b-actin mRNA. 14 The cDNA used in the following reverse transcription (RT)-PCR was adjusted according to the quantity of b-actin mRNA. The primer sequences for DRP1 were 5 0 -AATCCTAATTCCATTATCCTCGCT-3 0 (nts 598-621, NM_005690.2) and 5 0 -ACCAGTAGCATTTC TAATGGC-3 0 (nts 1275-1255). The amplified products were analyzed on 1% agarose gel, and visualized by ethidium bromide staining. The DRP1 fragment was 678 bp. The cDNA was inserted into plasmid pCRII and the DNA sequence was determined by an automatic DNA sequencer (ABI PRISM; PerkinElmer Applied Biosystems, Foster City, CA, USA). The DNA sequence corresponding to the N-terminal amino acids 48-226 was amplified by primer sequences containing EcoRI (sense) and SalI (antisense) restriction sites, respectively. The primer sequences were 5 0 -TCCGAATTCATGGACCTGCTT CCCAGAGGTACT-3 0 (EcoRI site is underlined) and 5 0 -TTGTCGACGTCACTAGGCATCAGTACCCGCATC-3 0 (SalI site is underlined).
The 534 bp cDNA of DRP1 was cloned into the expression vector pET-32b þ (pET32 þ -AIF; Promega KK, Tokyo, Japan). Bacterial colonies containing the pET32 þ -DLP were selected, and induced by isopropyl-b-D-thiogalactopyranoside to mass-produce AIF. The recombinant protein was purified by a nickel-affinity column, and protein identity was determined by MALDI-TOF. Affinity-purified DRP1 fragments were used to immunize BALB/c mice, and sensitivity of antiserum (OD 405 40.6 at 1:3000 dilutions) was measured by enzyme-linked immunosorbent assay. Specificity of antibodies was validated when discrete bands with a molecular weight of 80 kDa on the immunoblot of the lung cancer cell extract were detected. In some cases, protein bands 480 kDa appeared. 6 Monoclonal antibodies were produced by a hybridoma technique, and DRP1-specific antibodies were screened by the above-mentioned methods.
Immunoprecipitation, Gel Electrophoresis and Protein Analysis by MALDI-TOF
Total cell lysate was prepared by mixing 5 Â 10 7 cells per 100 ml phosphate-buffered saline (PBS) with an equal volume of 2 Â NP-40 lysis buffer (40 mM Tris-HCl (pH 7.6), 2 mM EDTA, 300 mM NaCl, 2% NP-40 and 2 mM phenylmethylsulfonylfluoride (PMSF)). The Protein G Sepharose (Amersham Biosciences AB, Uppsala, Sweden) was prewashed before mixing with 500 mg of total cell lysate. The reaction mixture was incubated at 41C for 60 min, and then centrifuged at 800 g for 1 min. The supernatant was reacted with 5 mg of purified monoclonal antibodies and 20 ml of fresh Protein G Sepharose at 41C for 18 h. The reaction mixture was centrifuged at 800 g for 1 min. Following removal of the supernatant, the precipitate was washed with 1 Â PBS, and dissolved in loading buffer (50 mM Tris (pH 6.8), 150 mM NaCl, 1 mM disodium EDTA, 1 mM PMSF, 10% glycerol, 5% b-mercaptoethanol, 0.01% bromophenol blue and 1% SDS). Eletrophoresis was carried out on two 10% polyacrylamide gels with 4.5% stacking. One gel was processed for immunoblotting, 15 and the other was stained with Coomassie blue. Protein bands on the Coomassie-stained gel, which corresponded to the immunoblotting-positive bands, were extracted from the gel for identification by MALDI-TOF on a Voyager-DE Pro Biospectrometry Workstation (Applied Biosystems, Milpitas, CA, USA). Fragments of peptide fingerprints were matched with those on the SwissProt database by MS-Fit (ProteinProspector 4.0.5, The Regents of the University of California). After electrophoresis, proteins on the first gel were transferred to a nitrocellulose membrane for immunoblotting. The membrane was probed with specific antibodies. The signal was amplified by biotin-labeled goat anti-mouse IgG, and peroxidase-conjugated streptavidin. The protein was visualized by exposing the membrane to an X-Omat film (Eastman Kodak, Rochester, NY, USA) with enhanced chemiluminescent reagent (NEN, Boston, MA, USA).
Fractionation of Cellular Components
Fractionation of subcellular components was performed according to the manufacturer's instructions (Calbiochem: http://www.merckbiosciences.co.uk) with minor modifications. The cells were detached from culture plates by treating them with dissociation buffer (Sigma, St Louis, MO, USA) at 371C for 2-5 min. After washing with PBS, the cells were resuspended in homogenization buffer (10 mM Tris-HCl (pH 7.4), 10 mM KCl, 1.5 mM MgCl 2 , 1 mM Na-EDTA, 1 mM Na-EGTA, 1 mM dithiothreitol, 250 mM sucrose, 0.1 mM PMSF, leupeptin (10 mg/ml), aprotinin (10 mg/ml) and trypsin inhibitor (10 mg/ml)) at 41C for 15 min. After 80 strokes with a B pestle in a douncer, the unbroken cells were removed by centrifugation at 30 g for 5 min. The nuclei were collected by spinning the solution at 80 g for 10 min, and mitochondria were collected from the supernatant by centrifugation at 6000 g for 20 min. Following centrifugation at 20 000 g for 20 min to remove the insoluble residue, the final supernatant was used as the cytosolic fraction.
Immunoblotting, Immunological and Immunofluorescent Staining
The procedure for immunoblotting has been described previously. 15 Briefly, proteins were separated on a 10% polyacrylamide gel with 4.5% stacking gel. After electrophoresis, proteins were transferred to a nitrocellulose membrane. The membrane was then probed with specific antibodies. The protein was visualized by exposing the membrane to an X-Omat film (Eastman Kodak) with enhanced chemiluminescent reagent (NEN). The same antibodies were used for immunohistochemistry and immunofluorescence confocal microscopy. Immunological staining was performed by an immunoperoxidase method as previously described. 14 For immunofluorescence staining, MitoTracker Green FM (Molecular Probes Inc., Eugene, OR, USA) was used to label mitochondria, and nuclei were stained with 4 0 ,6-diamidino-2-phenylindole (DAPI). Slides were examined under a laser scanning confocal microscope (LSM510; Zeiss, Chicago, IL, USA).
Cytotoxicity Assay
Cells were seeded at 1000, 2500 and 5000 cells per well 18 h before drug challenge. The cells were treated continuously with various concentrations of cisplatin (range, 1.6 mM to 1.0 mM) for 72 h. Following drug challenge, 10 ml of WST-1 (BioVision, Mountain View, CA, USA) was added and incubation was continued for 2 h. Percent survival of cells was quantified by comparing the number of viable cells in the treatment group with those in the control group. All procedures were performed in triplicate.
Slide Evaluation
In each pathological section, non-tumor lung tissues were served as the internal negative control.
14 Slides were evaluated by two independent pathologists without clinicopathological knowledge. Strong and moderate signals were indicative of DRP1 overexpression; weak or negative signals indicated low expression of DRP1.
Statistical Analysis
The relationship between DRP1 expression and clinicopathological parameters was analyzed by w 2 -test or w 2 -test for trend when a clinicopathological parameter was over two categories. Survival curves were plotted using the Kaplan-Meier estimator 16 and GraphPad Prism5 statistical software (GraphPad, San Diego, CA, USA). Statistical difference in survival among different groups was compared by the log-rank test 17 and log-rank test for trend. Univariate and multivariate analyses were performed using SPSS statistical software (SPSS Inc., Chicago, IL, USA). A P-value o0.05 was taken as being statistically significant.
Results
Functional Characterization of Monoclonal Antibodies to DRP1
Specificity of monoclonal antibodies was determined by an immunoblotting analysis of whole-cell lysate. Three protein bands of approximately 80 kDa were detected by the antibodies (Figure 1a ). Protein bands higher than 80 kDa indicated phosphorylated DRP1, 6 which were sensitive to alkaline phosphatase (Figure 1b) . DRP1 level varied among cancer cells: the level was high in H838, H23, H2009 and H226 cells, and moderate in H2087, A549 and HeLa cells. H1437 cells only minimally expressed DRP1. Expression of DRP1 was confirmed by RT-PCR. Specificity of amplified cDNA fragments was verified by DNA sequencing, and DNA sequencematched DRP1 (NM_012063, www.ncbi.nlm.nih. gov/GenBank database). No polymorphism or mutation was found. It is worth noting that no significant difference was found in expression levels of DRP1 mRNA; thus, the marked variation in protein levels could be resulted from translation efficiency in different cancer cells. Protein precipitated by antibodies was characterized by MALDI-TOF. The peptide mass fingerprint matched that of DRP1: O00429, DRP1. Immunocytochemical staining showed that DRP1 was abundantly present in cancer cells (MS-Fit search, http://prospector.ucsf.edu/). The granular appearance of the subcellular structures suggested that DRP1 was present in mitochondria, nucleoli and transport vesicles, eg, peroxisomes. 5 Confocal immunofluorescence images confirmed that DRP1 was located in mitochondria, nucleoli ( Figure 1c1 ) and peroxisomes (Figure 1c2 ). Treatment with siRNA markedly decreased DRP1 expression (Figure 1d1) , only a few residual DRP1 retained on mitochondria and mitochondria became The protein band (pDRP1) with a molecular weight higher than 80 kDa (DRP1) was sensitive to alkaline phosphatase (AP). (c) Distribution of DRP1 as determined by immunofluorescence confocal microscopy. (c1) H838 cells were fed with MitoTracker Green FM (mitochondria-specific dye, green fluorescence) before stained with DRP1-specific monoclonal antibodies labeled with rhodamine (red fluorescence). In merged images, the yellow fluorescence, which was enhanced when red and green fluorescence overlapped at the same location, confirmed that DRP1 was located on mitochondria. The remaining red fluorescent specks indicated that DRP1 was also distributed in nucleoli (arrows) and other organelles. (c2) Confocal immunofluorescence cytochemistry showed that DRP1 (labeled with rhodamine, red fluorescence) was located on peroxisome (labeled with GFP, a green fluorescent protein), as the merged images (the yellow fluorescence), which was produced when red and green fluorescence overlapped at the same spot. Nuclei were stained with blue fluorescent dye 4 0 ,6-diamidino-2-phenylindole (DAPI). filamentous (Figure 1d2 ). These results validated that our monoclonal antibodies recognized DRP1.
Expression of DRP1 in Lung Adenocarcinomas and Correlation with Patients' Survival
Using DRP1-specific monoclonal antibodies, we detected DRP1 overexpression in tumor cells in specimens from 202 patients (89.0%) with lung adenocarcinomas (Figure 2a1 and a2) . The DRP1 signal was identified in nuclei of tumor cells ( Figure  2a2 ) in 184 (91.1%) of the 202 patients. Nuclear DRP1 (DRP1 nuc ) was detected in 91.2% (52 of 57) of metastatic lymph nodes. Interestingly, some of the nuclear DRP1 signal was located in nucleoli ( Figure  2a2 ). Overexpression of DRP1 (17 of 20) in tumor specimens was verified by immunoblotting ( Figure  2b ). Statistical analysis showed that expression of DRP1 nuc correlated with tumor staging and cigarette smoking (Tables 1 and 2 nuc was 3.41-fold higher than that in patients with DRP1 cyt . The difference was significant (Po0.01). No significant difference was found in cumulative survival between patients with high DRP1 levels and those with low DRP1 levels (Figure 2c1 ). However, survival of patients with high DRP1 cyt levels was significantly better than survival of patients with high DRP1 nuc levels and those in whom DRP1 was not detected (Figure 2c2 and c3 ; Po0.001). When patients were divided into groups by each of clinicopathological parameters, significant difference by univariate analysis was found in tumor stage (Po0.001), lymph node involvement (Po0.001), DRP1 expression (Po0.001) and gender (P ¼ 0.0294) ( Table 3) . In multivariate analysis, tumor stage (Po0.001), lymph node involvement (P ¼ 0.004) and DRP1 expression (P ¼ 0.135) remained significant. No statistical difference was found in cell differentiation or cigarette smoking.
Increased Nuclear Localization of DRP1 and Survival Following Exposure to Hypoxia in Lung Adenocarcinoma Cells
In vitro, exposure to hypoxic conditions did not affect mRNA level of hypoxia-inducible factor-1a (HIF-1a) or DRP1 (Figure 3a1 ) in H838 cells, but significantly influenced the protein levels of HIF-1a and phosphorylated DRP1 (Figure 3a2 ). Partial degradation of DRP1 in the early phase of hypoxia (around 1-3 h) suggested that DRP1 could be labile in the cytoplasm. Hypoxia increased cell resistance to cisplatin (Figure 3b) as well as the levels of nuclear and nucleolar DRP1, which were determined by confocal immunofluorescence microscopy ( Figure 3c , the second row of images). Knockdown of human homologue of yeast Rad23 protein A (hHR23A), however, decreased hypoxia-induced cytoprotection of cisplatin toxicity in H838 cells. Earlier treatment with RNAse, however, reduced nucleolar levels of DRP1 (Figure 3c , the third row of images). Immunoblotting analysis of subcellular components confirmed our findings that DRP1 was located in the nucleus following exposure to hypoxia (Figure 3d ). The nuclear DRP1 was mostly phosphorylated. Overexpression of ectopic DRP1 WT , but not DRP1 K38A , 9 increased nucleolar DRP1 and autophagic vesicles indicating that excessive cytoplasmic DRP1 could be able to trigger autophagy and became harmful to cells (Figure 3e ). Hypoxia also increased the formation of autophagic vesicles, which were encircled by hHR23A and DRP1 ( Figure  3f ). However, protein sequence analysis did not show that DRP1 contains a nuclear localization signal (Supplementary Figure 1) . Nuclear translocation of DRP1 might, thus, require a transporting vehicle. Using DRP1 as bait to screen a cytoplasmic protein library, we found that hHR23A reacted with DRP1.
Antibodies Specific to DRP1 Precipitates hHR23A and Repression of hHR23A Expression Decreases Hypoxia-Induced Nuclear Translocation of DRP1
We used immunoprecipitation method to verify that DRP1 interacts with hHR23A. Monoclonal antibodies specific to DRP1 precipitated both DRP1 and hHR23A (Figure 4a, left panel) from the wholecell lysate. Likewise, monoclonal antibodies specific to hHR23A precipitated both hHR23A and DRP1 (Figure 4a, center panel) . Using monoclonal antibodies specific to green fluorescent protein (GFP), we precipitated both hHR23A and DRP1-EGP, of which an enhanced green fluorescent protein (EGP) was conjugated at the C terminus of DRP1, as well as pDRP1-EGP (Figure 4a , right panel). These results suggest that DRP1 directly interacts with hHR23A.
Interestingly, using hHR23A-specific siRNAs to knock down hHR23A expressions also reduced protein levels of DRP1 (Figure 4b, left panel) . Ectopic replenish of hHR23A expression recovered DRP1 expression (Figure 4b, right panel) . The phenomena were confirmed by confocal immunofluorescence microscopy ( Figure 4c , the second row of images). Although short-term hypoxia increased nuclear and nucleolar DRP1 (Figure 4c , the third row of images), silence of hHR23A expression clearly decreased nuclear translocation of DRP1 (Figure 4c , fourth row of images). These results suggest that hHR23A is involved in nuclear transportation of DRP1.
DRP1 Interacts with AMPK and Silence of AMPK Expression Decreases DRP1 Phosphorylation
Antibodies specific to AMP-activated protein kinase (AMPK) precipitated both AMPK and DRP1 from cell lysate of H838 cells (Figure 5a ), indicating that AMPK and DRP1 interacted with each other. Silence of AMPK expression by siRNA reduced hypoxia-induced DRP1 phosphorylation (Figure 5b ), suggesting that AMPK is involved in phosphorylation of DRP1 during hypoxia.
Discussion
The results show that antibodies generated in this study recognized the functional DRP1, which is normally present on mitochondria, [5] [6] [7] [8] as well as nuclear and nucleolar DRP1 (DRP1 nuc ), which is frequently detected in pathological sections of lung adenocarcinomas and in hypoxic cells. Correlation of DRP1 nuc expression with the advanced tumor stage and patients' cigarette-smoking habits suggests that DRP1 nuc expression is associated with cigarette smoking, and, possibly, the hypoxic environment. In vitro, hypoxia increased levels of DRP1 nuc expression and that of drug resistance in lung þ , high DRP1 expression. Survival difference between the two groups was compared by a log-rank test (P ¼ 0.3871). (c2) Patients were divided into three groups based on DRP1 expression and location of DRP1 in the lung adenocarcinoma cells. The survival rate of patients in the group with cytoplasmic DRP1 only (DRP1 cyt þ ) was better than that of patients in the other two groups: DRP1 À and DRP1 nucleus-positive (DRP1 nuc þ ) groups. Survival difference between the three groups was compared by a log-rank test for trend (Po0.01). (c3) The difference was also significant when DRP1 À and DRP1 nuc þ groups were pooled and the survival was compared by a log-rank test (Po0.001).
cancer cells. Moreover, these data indicate that intracellular distribution of DRP1 is essential for determining drug sensitivity of lung adenocarcinomas, which then reflects in patients' survivals. Patients, who have DRP1 in cytoplasm, probably on mitochondria, are more sensitive to chemotherapy and have better prognosis. Conversely, patients, who have undetectable level of cytoplasmic DRP1 or those in whom DRP1 is sequestered to the nucleus are more resistant to chemotherapy and, therefore, have worse prognosis.
Hypoxia is frequently detected in advanced solid tumors and is associated with increased drug resistance in cancer cells. 18, 19 The increase in drug resistance has been attributed to the expression of multidrug resistance 1 protein, MDR-associated protein and antiapoptotic Bcl-2 protein. Interestingly, hypoxia and genotoxic stress have also been reported to increase nuclear levels of apoptosisrelated mitochondrial proteins, eg, Bcl-2, Bcl-2 19 kDa interacting protein 3 (BNIP3), 20 ,21 apoptotic protease-activating factor 1 and 'BH3-only' proapoptotic protein BID. [21] [22] [23] [24] These proteins do not contain evident nuclear localization signals, but they do contain a potential DNA-and RNA-binding motifs (Supplementary Figure 1) and they are 'located in the nucleus' when cells were exposed to hypoxia or genotoxic stress. Recent studies have shown that these proteins are involved in cell-cycle progression and DNA repair, processes that are mediated by ataxia telangiectasia mutated (ATM) as well as ATM and rad3-related (ATR) kinases. Nuclear localization of these proteins could increase genomic instability as well as radiation and drug resistance. 24, 25 However, nuclear transportation mechanisms of these proteins are not clearly illustrated.
It is worth noting that DRP1 has been detected in the 'nuclei and nucleoli'. 9, [26] [27] [28] The nuclear and nucleolar accumulation became more evident when cells were exposed to hypoxia. Increased nuclear levels of DRP1 correlated with drug resistance. Moreover, using antibodies specific to DRP1 and hHR23A, we found that these two proteins interact with each other. Silencing of hHR23A reduces the levels of DRP1 nuc and cisplatin resistance. These data suggest that hHR23A is essential for the accumulation of DRP1 nuc and for cisplatin resistance. It should be noted, however, that other explanations are possible. For instance, like yeast Rad23 human homologues, hHR23A and hHR23B have been proposed having crucial functions in nucleotide excision repair. 29 Nuclear imports of hHR23A and hHR23B are crucial for adequate DNA repair. Nuclear transport of these two proteins, which do not contain evident NLS, however, has not been clearly illustrated. The fact that knockout of hHR23B but not that of hHR23A gene in mice generated severe facial disfigurement and male infertility suggests that the physiological functions of hHR23A might be different from those of hHR23B. 30 Withers-Ward et al 31 showed that hHR23A, by interacting with viral protein R of human immunodeficiency virus (HIV), facilitates nuclear import of pre-integration complex for HIV replication. The presence of hHR23A inhibits p53 degradation and increases apoptosis, 32 which could be possibly through the association with p14ARF to sequester human double minute 2 (HDM2) protein in nucleoli and to relieve nuclear p53 from HDM2-mediated proteolysis. 33 These results, considered together with our current data, clearly suggest that hHR23A as well as karyopherins 34 might be important in emergency nuclear transport of DRP1 to protect genomic and nucleolar DNA when cells are subjected to hypoxic conditions (Supplementary Figure 2) .
As noted above, BNIP3, an important ARM protein, induces PCD through apoptosis and autophagy. 20, 21 Increased nuclear level of BNIP3, on the other hand, reduces cell sensitivity to hypoxia-and ischemia-induced damages. 21 Interestingly, DRP1 is involved in all three types of PCD. [2] [3] [4] The current study showed that hypoxia increased the nuclear levels of DRP1 and the level of cisplatin resistance in lung adenocarcinoma cells. In an elegant review, Conradt 35 proposed that DRP1 might be recruited by an X factor that promotes DRP1 binding to hFis1 on mitochondrial outer membrane and initiates mitochondrial fission. However, Conradt's hypothesis did not offer a mechanism of DRP1 activation. Our results, more or less, suggest that hHR23A might act as an X factor, which was activated by hypoxia, to protect cells by redistributing DRP1 to the nucleus (1) to prevent excessive mitochondrial fission or (2) to guard genomic DNA and nucleolar RNA against hypoxia-induced damage through a potential nucleotide-binding motif on DRP1 (Supplementary Figure 1) . In this case, our results provide a reasonable explanation for the involvement of DRP1, a mechanoenzyme that mediates organelle membrane constrictions, 7, 8 in type II programmed cell death and in the formation of autophagic vesicles, [2] [3] [4] which were corralled by both DRP1 and hHR23A. In particular, when cells were exposed to short-term hypoxia, the autophagic vacuoles as well as nuclear and nucleolar DRP1 emerged more prominently.
Taguchi et al 6 showed that DRP1 phosphorylation by cyclin-dependent kinase 1 (cdk1)/cyclin B is critical for mitochondrial fission during the mitotic (M) phase. Interestingly, cdk1/cyclin B protein complex is regulated by ATM/ATR kinases, which are transported in and out of the nucleus depending on the progression phases of cell cycle. 36, 37 Our data, which show that phosphorylation and nuclear translocation of DRP1 occur simultaneously with the increase in HIF-1a, support their findings. Moreover, our data show that the level of DRP1 rises during the S phase. The extent of DRP1 phosphorylation, however, is not changed throughout the cell-cycle progression (Supplementary Figure 3) . These results are consistent with the fact that although anticancer drugs induce growth arrest of cells at G 2 /M, the major cytotoxic function is S-phase dependent. 15 Moreover, because short-term hypoxia alone does not immediately induce visible DNA damage in cancer cells per se, by showing that DRP1 interacts with AMPK, and that silencing of AMPK reduces phosphorylation and nuclear translocation of DRP1, our data clearly indicate that AMPK is responsible for hypoxia-related phosphorylation of DRP1, 38, 39 and hHR23A binds phosphorylated DRP1.
In conclusion, immunohistochemistry revealed abundant nuclear expression of DRP1 in lung adenocarcinomas. Pathological results suggest that nuclear and nucleolar DRP1 (DRP1 nuc ) are associated with poor prognosis. In vitro, hypoxia increased the expression of DRP1 nuc and the level of cisplatin resistance in lung adenocarcinoma cells. By showing that DRP1 and hHR23A interact with each other, and that silencing of hHR23A decreased the nuclear translocation of DRP1 as well as cisplatin resistance, our results suggest that nuclear transport of pDRP1 might have a role in increasing drug resistance of lung cancer cells during hypoxia.
